| 630 | Humans (MeSH) |
| 517 | Respiratory Distress Syndrome, Adult (therapy) |
| 447 | Prone Position (MeSH) |
| 269 | Male (MeSH) |
| 240 | Female (MeSH) |
| 230 | Respiratory Distress Syndrome, Adult (physiopathology) |
| 197 | Adult (MeSH) |
| 187 | Middle Aged (MeSH) |
| 171 | Respiration, Artificial (methods) |
| 130 | Respiration, Artificial (MeSH) |
| 127 | Prone Position (physiology) |
| 119 | Positive-Pressure Respiration (MeSH) |
| 116 | Aged (MeSH) |
| 105 | Treatment Outcome (MeSH) |
| 96 | Respiratory Distress Syndrome, Adult (etiology) |
| 91 | Respiratory Distress Syndrome, Adult (mortality) |
| 82 | Prospective Studies (MeSH) |
| 72 | Critical Care (methods) |
| 70 | Positive-Pressure Respiration (methods) |
| 69 | Pulmonary Gas Exchange (MeSH) |
| 66 | Respiration, Artificial (adverse effects) |
| 61 | Animals (MeSH) |
| 54 | Hypoxia (therapy) |
| 54 | Hemodynamics (MeSH) |
| 54 | Blood Gas Analysis (MeSH) |
| 53 | Extracorporeal Membrane Oxygenation (MeSH) |
| 51 | Oxygen (blood) |
| 49 | Time Factors (MeSH) |
| 49 | Supine Position (MeSH) |
| 49 | Respiratory Distress Syndrome, Adult (diagnosis) |
| 49 | Patient Positioning (methods) |
| 48 | Tidal Volume (MeSH) |
| 45 | Respiratory Distress Syndrome, Adult (diagnostic imaging) |
| 42 | Retrospective Studies (MeSH) |
| 42 | Respiratory Mechanics (MeSH) |
| 42 | Respiratory Distress Syndrome, Adult (complications) |
| 41 | Lung (physiopathology) |
| 41 | Adolescent (MeSH) |
| 39 | Respiratory Insufficiency (therapy) |
| 39 | Patient Positioning (MeSH) |
| 38 | Intensive Care Units (MeSH) |
| 37 | Tomography, X-Ray Computed (MeSH) |
| 37 | Severity of Illness Index (MeSH) |
| 36 | Respiratory Distress Syndrome, Adult (nursing) |
| 36 | Respiratory Distress Syndrome, Adult (metabolism) |
| 35 | Randomized Controlled Trials as Topic (MeSH) |
| 35 | Nitric Oxide (therapeutic use) |
| 33 | Risk Factors (MeSH) |
| 33 | Nitric Oxide (administration & dosage) |
| 32 | Extracorporeal Membrane Oxygenation (methods) |
| 32 | Child (MeSH) |
| 29 | Pulmonary Gas Exchange (physiology) |
| 29 | Pandemics (MeSH) |
| 28 | Posture (MeSH) |
| 28 | Hypoxia (etiology) |
| 28 | High-Frequency Ventilation (MeSH) |
| 28 | Critical Care (MeSH) |
| 28 | Administration, Inhalation (MeSH) |
| 27 | Supine Position (physiology) |
| 27 | Respiratory Mechanics (physiology) |
| 23 | Respiratory Distress Syndrome, Adult (blood) |
| 23 | Disease Models, Animal (MeSH) |
| 23 | Aged, 80 and over (MeSH) |
| 22 | Respiratory Function Tests (MeSH) |
| 22 | Respiratory Distress Syndrome, Adult (MeSH) |
| 22 | Practice Guidelines as Topic (MeSH) |
| 22 | Lung (diagnostic imaging) |
| 21 | Acute Lung Injury (therapy) |
| 21 | Acute Disease (MeSH) |
| 20 | Pneumonia, Viral (therapy) |
| 20 | Combined Modality Therapy (MeSH) |
| 19 | Ventilator-Induced Lung Injury (prevention & control) |
| 19 | Respiratory Distress Syndrome, Adult (drug therapy) |
| 19 | Pulmonary Surfactants (therapeutic use) |
| 19 | Oxygen (metabolism) |
| 19 | Coronavirus Infections (therapy) |
| 19 | Betacoronavirus (MeSH) |
| 18 | Survival Rate (MeSH) |
| 18 | Prognosis (MeSH) |
| 18 | Patient Positioning (adverse effects) |
| 18 | Neuromuscular Blocking Agents (therapeutic use) |
| 18 | Lung (pathology) |
| 17 | Respiratory Distress Syndrome, Adult (prevention & control) |
| 17 | Respiratory Distress Syndrome, Adult (pathology) |
| 17 | Infant, Newborn (MeSH) |
| 17 | Infant (MeSH) |
| 17 | Analysis of Variance (MeSH) |
| 16 | Swine (MeSH) |
| 16 | APACHE (MeSH) |
| 15 | Young Adult (MeSH) |
| 15 | Survival Analysis (MeSH) |
| 15 | Random Allocation (MeSH) |
| 15 | Pulmonary Ventilation (MeSH) |
| 15 | Patient Selection (MeSH) |
| 15 | Clinical Trials as Topic (MeSH) |
| 15 | Child, Preschool (MeSH) |
| 14 | Respiratory Insufficiency (physiopathology) |
| 14 | Respiration (MeSH) |
| 14 | Monitoring, Physiologic (MeSH) |
| 14 | Evidence-Based Medicine (MeSH) |
| 14 | Dogs (MeSH) |
| 14 | Adrenal Cortex Hormones (therapeutic use) |
| 13 | Vasodilator Agents (therapeutic use) |
| 13 | Respiratory Insufficiency (etiology) |
| 13 | Pulmonary Alveoli (physiopathology) |
| 13 | Pressure Ulcer (etiology) |
| 13 | Pneumonia, Viral (complications) |
| 13 | Oxygen Consumption (MeSH) |
| 13 | Hospital Mortality (MeSH) |
| 13 | Hemodynamics (physiology) |
| 12 | Statistics, Nonparametric (MeSH) |
| 12 | Respiratory Distress Syndrome, Newborn (therapy) |
| 12 | Respiratory Distress Syndrome, Adult (epidemiology) |
| 12 | Pulmonary Circulation (MeSH) |
| 12 | Hypoxia (physiopathology) |
| 12 | Fluid Therapy (MeSH) |
| 12 | Critical Illness (MeSH) |
| 12 | Coronavirus Infections (complications) |
| 12 | Carbon Dioxide (blood) |
| 12 | Acute Lung Injury (physiopathology) |
| 11 | Ventilation-Perfusion Ratio (MeSH) |
| 11 | Tidal Volume (physiology) |
| 11 | Radiography (MeSH) |
| 11 | Positive-Pressure Respiration (adverse effects) |
| 11 | Lung Compliance (MeSH) |
| 11 | Intubation, Intratracheal (MeSH) |
| 11 | Incidence (MeSH) |
| 10 | Respiratory Distress Syndrome, Adult (virology) |
| 10 | Pressure (MeSH) |
| 10 | Predictive Value of Tests (MeSH) |
| 10 | Partial Pressure (MeSH) |
| 10 | Oxygen Inhalation Therapy (MeSH) |
| 10 | Meta-Analysis as Topic (MeSH) |
| 10 | Lung Compliance (physiology) |
| 10 | Hypoxia (mortality) |
| 10 | High-Frequency Ventilation (methods) |
| 10 | Beds (MeSH) |
| 9 | Postoperative Complications (therapy) |
| 9 | Pilot Projects (MeSH) |
| 9 | Nurse's Role (MeSH) |
| 9 | Monitoring, Physiologic (methods) |
| 9 | Lung Volume Measurements (MeSH) |
| 9 | Liquid Ventilation (MeSH) |
| 9 | Hypoxia (complications) |
| 9 | Algorithms (MeSH) |
| 8 | Respiratory Insufficiency (mortality) |
| 8 | Respiration, Artificial (mortality) |
| 8 | Oleic Acid (MeSH) |
| 8 | Multiple Trauma (complications) |
| 8 | Lung (physiology) |
| 8 | Length of Stay (MeSH) |
| 8 | Intensive Care Units (statistics & numerical data) |
| 8 | Critical Care (standards) |
| 8 | Bronchodilator Agents (therapeutic use) |
| 7 | Ventilators, Mechanical (MeSH) |
| 7 | Risk Assessment (MeSH) |
| 7 | Respiratory Therapy (MeSH) |
| 7 | Respiratory Distress Syndrome, Adult (classification) |
| 7 | Respiration, Artificial (nursing) |
| 7 | Pulmonary Alveoli (physiology) |
| 7 | Posture (physiology) |
| 7 | Pneumonia, Viral (physiopathology) |
| 7 | Multivariate Analysis (MeSH) |
| 7 | Kaplan-Meier Estimate (MeSH) |
| 7 | Injury Severity Score (MeSH) |
| 7 | Influenza, Human (complications) |
| 7 | Coronavirus Infections (physiopathology) |
| 7 | Bronchodilator Agents (administration & dosage) |
| 6 | Wounds and Injuries (complications) |
| 6 | Ventilator-Induced Lung Injury (etiology) |
| 6 | Vasodilator Agents (administration & dosage) |
| 6 | Rotation (MeSH) |
| 6 | Respiratory Insufficiency (diagnosis) |
| 6 | Respiration, Artificial (standards) |
| 6 | Research Design (MeSH) |
| 6 | Pressure Ulcer (prevention & control) |
| 6 | Pneumonia, Ventilator-Associated (prevention & control) |
| 6 | Patient Care Planning (MeSH) |
| 6 | Nursing Assessment (MeSH) |
| 6 | Multiple Trauma (therapy) |
| 6 | Lung Injury (MeSH) |
| 6 | Lung (metabolism) |
| 6 | Influenza, Human (therapy) |
| 6 | Influenza A Virus, H1N1 Subtype (MeSH) |
| 6 | Hemodynamics (drug effects) |
| 6 | Fluorocarbons (therapeutic use) |
| 6 | Fluid Therapy (methods) |
| 6 | Feasibility Studies (MeSH) |
| 6 | Acute Lung Injury (mortality) |
| 5 | Ventilator Weaning (MeSH) |
| 5 | Subarachnoid Hemorrhage (complications) |
| 5 | Shock, Septic (therapy) |
| 5 | Sheep (MeSH) |
| 5 | Safety (MeSH) |
| 5 | Respiratory Therapy (methods) |
| 5 | Respiratory System Agents (therapeutic use) |
| 5 | Respiratory Distress Syndrome, Adult (microbiology) |
| 5 | Respiratory Distress Syndrome, Adult (chemically induced) |
| 5 | Rabbits (MeSH) |
| 5 | Pulmonary Gas Exchange (drug effects) |
| 5 | Pulmonary Edema (physiopathology) |
| 5 | Pulmonary Atelectasis (therapy) |
| 5 | Pulmonary Atelectasis (etiology) |
| 5 | Prevalence (MeSH) |
| 5 | Pregnancy (MeSH) |
| 5 | Pneumonia, Viral (epidemiology) |
| 5 | Pneumonia, Viral (diagnosis) |
| 5 | Patient Positioning (mortality) |
| 5 | Oxygen Inhalation Therapy (methods) |
| 5 | Oxygen (physiology) |
| 5 | Logistic Models (MeSH) |
| 5 | Linear Models (MeSH) |
| 5 | Hospitals, University (MeSH) |
| 5 | Glucocorticoids (therapeutic use) |
| 5 | Extracorporeal Membrane Oxygenation (instrumentation) |
| 5 | Extracorporeal Membrane Oxygenation (adverse effects) |
| 5 | Equipment Design (MeSH) |
| 5 | Disease Management (MeSH) |
| 5 | Cross-Over Studies (MeSH) |
| 5 | Coronavirus Infections (epidemiology) |
| 5 | Coronavirus Infections (diagnosis) |
| 5 | Cohort Studies (MeSH) |
| 5 | Case-Control Studies (MeSH) |
| 5 | Cardiac Output (MeSH) |
| 5 | Acute Lung Injury (etiology) |
| 4 | Vasoconstrictor Agents (therapeutic use) |
| 4 | Tomography, X-Ray Computed (methods) |
| 4 | Surveys and Questionnaires (MeSH) |
| 4 | Subarachnoid Hemorrhage (therapy) |
| 4 | Stress, Mechanical (MeSH) |
| 4 | Sepsis (complications) |
| 4 | Respiratory System Agents (administration & dosage) |
| 4 | Respiratory Insufficiency (complications) |
| 4 | Respiration, Artificial (trends) |
| 4 | Research Design (standards) |
| 4 | Reproducibility of Results (MeSH) |
| 4 | Rats (MeSH) |
| 4 | Radiography, Thoracic (MeSH) |
| 4 | Proportional Hazards Models (MeSH) |
| 4 | Pneumothorax (etiology) |
| 4 | Pneumonia, Viral (virology) |
| 4 | Oxygen Consumption (physiology) |
| 4 | Oximetry (MeSH) |
| 4 | Organ Dysfunction Scores (MeSH) |
| 4 | Multiple Trauma (physiopathology) |
| 4 | Models, Biological (MeSH) |
| 4 | Liquid Ventilation (methods) |
| 4 | Length of Stay (statistics & numerical data) |
| 4 | Inflammation (MeSH) |
| 4 | Hypoxia (prevention & control) |
| 4 | Hypoxia (drug therapy) |
| 4 | Hypoxia (diagnosis) |
| 4 | Hypercapnia (physiopathology) |
| 4 | France (epidemiology) |
| 4 | France (MeSH) |
| 4 | Extracorporeal Membrane Oxygenation (standards) |
| 4 | Echocardiography, Transesophageal (MeSH) |
| 4 | Drainage (MeSH) |
| 4 | Diagnosis, Differential (MeSH) |
| 4 | Data Interpretation, Statistical (MeSH) |
| 4 | Continuous Positive Airway Pressure (methods) |
| 4 | Bronchoscopy (MeSH) |
| 4 | Almitrine (administration & dosage) |
| 4 | Airway Resistance (MeSH) |
| 4 | Abdomen (physiopathology) |
| 3 | Wounds, Nonpenetrating (complications) |
| 3 | Ventricular Dysfunction, Right (physiopathology) |
| 3 | Ventricular Dysfunction, Right (etiology) |
| 3 | Severe Acute Respiratory Syndrome (therapy) |
| 3 | Sensitivity and Specificity (MeSH) |
| 3 | Respiratory Function Tests (methods) |
| 3 | Respiratory Dead Space (MeSH) |
| 3 | Respiration, Artificial (statistics & numerical data) |
| 3 | Respiration, Artificial (instrumentation) |
| 3 | ROC Curve (MeSH) |
| 3 | Pulmonary Edema (therapy) |
| 3 | Pulmonary Edema (etiology) |
| 3 | Pulmonary Edema (diagnostic imaging) |
| 3 | Pulmonary Circulation (drug effects) |
| 3 | Pulmonary Atelectasis (physiopathology) |
| 3 | Pressure Ulcer (epidemiology) |
| 3 | Positron-Emission Tomography (MeSH) |
| 3 | Positive-Pressure Respiration, Intrinsic (MeSH) |
| 3 | Positive-Pressure Respiration (statistics & numerical data) |
| 3 | Positive-Pressure Respiration (standards) |
| 3 | Positive-Pressure Respiration (instrumentation) |
| 3 | Pneumonia, Viral (diagnostic imaging) |
| 3 | Pneumonia, Ventilator-Associated (etiology) |
| 3 | Pneumonia, Ventilator-Associated (epidemiology) |
| 3 | Pneumonia, Pneumococcal (complications) |
| 3 | Pneumonia (complications) |
| 3 | Platelet Aggregation Inhibitors (therapeutic use) |
| 3 | Physical Therapy Modalities (methods) |
| 3 | Physical Therapy Modalities (MeSH) |
| 3 | Patient Positioning (statistics & numerical data) |
| 3 | Oxygen (administration & dosage) |
| 3 | Oxygen (MeSH) |
| 3 | Outcome and Process Assessment, Health Care (MeSH) |
| 3 | Outcome Assessment, Health Care (MeSH) |
| 3 | Odds Ratio (MeSH) |
| 3 | Obesity, Morbid (complications) |
| 3 | Nutritional Support (MeSH) |
| 3 | Nitric Oxide (pharmacology) |
| 3 | Multiple Organ Failure (etiology) |
| 3 | Multicenter Studies as Topic (MeSH) |
| 3 | Monitoring, Physiologic (nursing) |
| 3 | Models, Animal (MeSH) |
| 3 | Lung Diseases, Interstitial (complications) |
| 3 | Lung (drug effects) |
| 3 | Lifting (MeSH) |
| 3 | Italy (MeSH) |
| 3 | Intracranial Pressure (MeSH) |
| 3 | Intensive Care Units, Pediatric (MeSH) |
| 3 | Inhalation (MeSH) |
| 3 | Inflammation Mediators (metabolism) |
| 3 | Hypertension, Pulmonary (therapy) |
| 3 | Gravitation (MeSH) |
| 3 | Germany (MeSH) |
| 3 | Functional Residual Capacity (MeSH) |
| 3 | Follow-Up Studies (MeSH) |
| 3 | Fluorocarbons (administration & dosage) |
| 3 | Fatal Outcome (MeSH) |
| 3 | Extravascular Lung Water (MeSH) |
| 3 | Evaluation Studies as Topic (MeSH) |
| 3 | Epoprostenol (therapeutic use) |
| 3 | Enteral Nutrition (MeSH) |
| 3 | Electric Impedance (MeSH) |
| 3 | Drug Evaluation, Preclinical (MeSH) |
| 3 | Diuretics (therapeutic use) |
| 3 | Disease Progression (MeSH) |
| 3 | Cross-Sectional Studies (MeSH) |
| 3 | Critical Illness (nursing) |
| 3 | Coronavirus Infections (virology) |
| 3 | Contraindications (MeSH) |
| 3 | Chronic Disease (MeSH) |
| 3 | Carbon Dioxide (metabolism) |
| 3 | Cannula (MeSH) |
| 3 | Bronchoalveolar Lavage Fluid (chemistry) |
| 3 | Blood Pressure (MeSH) |
| 3 | Bed Rest (nursing) |
| 3 | Almitrine (therapeutic use) |
| 3 | Air Ambulances (MeSH) |
| 3 | Adrenal Cortex Hormones (administration & dosage) |
| 3 | Acute Lung Injury (prevention & control) |
| 3 | Acute Lung Injury (diagnosis) |
| 3 | Acute Lung Injury (complications) |
| 2 | Wounds, Gunshot (therapy) |
| 2 | Work of Breathing (MeSH) |
| 2 | Wakefulness (MeSH) |
| 2 | Ventricular Dysfunction, Right (prevention & control) |
| 2 | Ventricular Dysfunction, Right (diagnostic imaging) |
| 2 | Ventilator-Induced Lung Injury (physiopathology) |
| 2 | Ventilation-Perfusion Ratio (physiology) |
| 2 | Vascular Resistance (drug effects) |
| 2 | Vascular Resistance (MeSH) |
| 2 | United States (MeSH) |
| 2 | Ultrasonography (methods) |
| 2 | Transportation of Patients (methods) |
| 2 | Trachea (physiopathology) |
| 2 | Total Lung Capacity (physiology) |
| 2 | Tomography (methods) |
| 2 | Thoracic Injuries (therapy) |
| 2 | Thoracic Injuries (complications) |
| 2 | Therapeutic Irrigation (MeSH) |
| 2 | Systematic Reviews as Topic (MeSH) |
| 2 | Survival Rate (trends) |
| 2 | Survival (MeSH) |
| 2 | Surface Tension (MeSH) |
| 2 | Suction (MeSH) |
| 2 | Standard of Care (MeSH) |
| 2 | Single-Blind Method (MeSH) |
| 2 | Severe Acute Respiratory Syndrome (mortality) |
| 2 | Salvage Therapy (methods) |
| 2 | Respiratory Physiological Phenomena (MeSH) |
| 2 | Respiratory Mechanics (drug effects) |
| 2 | Respiratory Insufficiency (metabolism) |
| 2 | Respiratory Insufficiency (epidemiology) |
| 2 | Respiratory Insufficiency (blood) |
| 2 | Respiratory Distress Syndrome, Newborn (physiopathology) |
| 2 | Respiratory Distress Syndrome, Adult (rehabilitation) |
| 2 | Respiratory Distress Syndrome, Adult (psychology) |
| 2 | Respiratory Distress Syndrome, Adult (immunology) |
| 2 | Respiratory Distress Syndrome, Adult (economics) |
| 2 | Renal Replacement Therapy (MeSH) |
| 2 | Renal Insufficiency (therapy) |
| 2 | Renal Insufficiency (etiology) |
| 2 | Recovery of Function (MeSH) |
| 2 | Randomized Controlled Trials as Topic (statistics & numerical data) |
| 2 | Randomized Controlled Trials as Topic (methods) |
| 2 | Quality of Life (MeSH) |
| 2 | Pulmonary Ventilation (physiology) |
| 2 | Pulmonary Surfactants (administration & dosage) |
| 2 | Pulmonary Heart Disease (therapy) |
| 2 | Pulmonary Heart Disease (physiopathology) |
| 2 | Pulmonary Heart Disease (etiology) |
| 2 | Pulmonary Heart Disease (diagnostic imaging) |
| 2 | Pulmonary Edema (MeSH) |
| 2 | Pulmonary Circulation (physiology) |
| 2 | Pulmonary Atelectasis (prevention & control) |
| 2 | Pulmonary Atelectasis (diagnostic imaging) |
| 2 | Prostaglandins I (therapeutic use) |
| 2 | Prostaglandins (therapeutic use) |
| 2 | Probability (MeSH) |
| 2 | Pressure Ulcer (therapy) |
| 2 | Pressure (adverse effects) |
| 2 | Pregnancy Complications, Infectious (therapy) |
| 2 | Practice Patterns, Physicians' (MeSH) |
| 2 | Postoperative Complications (physiopathology) |
| 2 | Postoperative Complications (etiology) |
| 2 | Postoperative Care (methods) |
| 2 | Pneumonia, Viral (transmission) |
| 2 | Pneumonia, Viral (metabolism) |
| 2 | Pneumonia, Mycoplasma (diagnosis) |
| 2 | Pneumonia, Mycoplasma (complications) |
| 2 | Pneumonia (therapy) |
| 2 | Pneumonia (prevention & control) |
| 2 | Patient Positioning (nursing) |
| 2 | Patient Positioning (instrumentation) |
| 2 | Patient Care Team (organization & administration) |
| 2 | Patient Care Team (MeSH) |
| 2 | Oxygen (chemistry) |
| 2 | Oxygen (analysis) |
| 2 | Organ Size (MeSH) |
| 2 | Obesity, Morbid (physiopathology) |
| 2 | Nursing (methods) |
| 2 | Noninvasive Ventilation (methods) |
| 2 | Noninvasive Ventilation (MeSH) |
| 2 | Nitric Oxide (metabolism) |
| 2 | Neuromuscular Blockade (methods) |
| 2 | Neuromuscular Blockade (MeSH) |
| 2 | Myositis Ossificans (etiology) |
| 2 | Mucociliary Clearance (MeSH) |
| 2 | Lung Transplantation (MeSH) |
| 2 | Lung Injury (prevention & control) |
| 2 | Lung Diseases, Interstitial (therapy) |
| 2 | Lung Diseases, Interstitial (diagnostic imaging) |
| 2 | Lung Diseases (therapy) |
| 2 | Lung Diseases (physiopathology) |
| 2 | Lung (blood supply) |
| 2 | Lung (MeSH) |
| 2 | Liver (metabolism) |
| 2 | Kinetics (MeSH) |
| 2 | Iraq War, 2003-2011 (MeSH) |
| 2 | Intubation, Intratracheal (adverse effects) |
| 2 | Interleukin-6 (metabolism) |
| 2 | Intensive Care Units (organization & administration) |
| 2 | Injections, Intravenous (MeSH) |
| 2 | Influenza, Human (virology) |
| 2 | Influenza, Human (epidemiology) |
| 2 | Influenza A Virus, H1N1 Subtype (isolation & purification) |
| 2 | Influenza A Virus, H1N1 Subtype (genetics) |
| 2 | Indocyanine Green (pharmacokinetics) |
| 2 | Iloprost (therapeutic use) |
| 2 | Iceland (epidemiology) |
| 2 | Hypoxia (epidemiology) |
| 2 | Hypoxia (blood) |
| 2 | Hypoxia (MeSH) |
| 2 | Hypertension (physiopathology) |
| 2 | Hypercapnia (therapy) |
| 2 | Hydrostatic Pressure (MeSH) |
| 2 | Hospitals, Teaching (MeSH) |
| 2 | Hospitals (statistics & numerical data) |
| 2 | Hospital Mortality (trends) |
| 2 | Hospital Costs (MeSH) |
| 2 | Hemothorax (therapy) |
| 2 | Hemorrhage (therapy) |
| 2 | Heart Ventricles (physiopathology) |
| 2 | Heart Arrest (therapy) |
| 2 | Heart Arrest (etiology) |
| 2 | Health Services Research (MeSH) |
| 2 | Glucocorticoids (administration & dosage) |
| 2 | Glasgow Coma Scale (MeSH) |
| 2 | Germany (epidemiology) |
| 2 | Free Radical Scavengers (therapeutic use) |
| 2 | Forecasting (MeSH) |
| 2 | Extracorporeal Membrane Oxygenation (mortality) |
| 2 | Extracorporeal Membrane Oxygenation (economics) |
| 2 | Extracorporeal Circulation (methods) |
| 2 | Extracorporeal Circulation (MeSH) |
| 2 | Evidence-Based Practice (MeSH) |
| 2 | Equipment Failure (MeSH) |
| 2 | Early Diagnosis (MeSH) |
| 2 | Dyspnea (MeSH) |
| 2 | Diffusion of Innovation (MeSH) |
| 2 | Diagnostic Imaging (MeSH) |
| 2 | Decision Trees (MeSH) |
| 2 | Cross Infection (epidemiology) |
| 2 | Critical Illness (therapy) |
| 2 | Critical Illness (mortality) |
| 2 | Coronavirus Infections (transmission) |
| 2 | Coronavirus Infections (metabolism) |
| 2 | Coronavirus Infections (drug therapy) |
| 2 | Continuous Positive Airway Pressure (instrumentation) |
| 2 | Continuous Positive Airway Pressure (MeSH) |
| 2 | Conscious Sedation (methods) |
| 2 | Conscious Sedation (MeSH) |
| 2 | Community-Acquired Infections (complications) |
| 2 | Combined Modality Therapy (methods) |
| 2 | Clinical Nursing Research (MeSH) |
| 2 | Clinical Competence (MeSH) |
